New drug aims to supercharge walking recovery after spinal cord injury
NCT ID NCT05217498
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called istradefylline can boost the walking improvements seen with low-oxygen therapy in people with chronic, incomplete spinal cord injury. About 40 adults aged 18-75 with injuries at least one year old will receive the drug or a placebo before walking practice. The goal is to see if blocking adenosine can make walking gains last longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Spaulding Rehabilitation Hospital
Cambridge, Massachusetts, 02138, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could music be medicine for the injured brain?
- Robots join the rehab team: a new hope for regaining movement?
- Can a sugar pill curb the opioid crisis?
- Testosterone may rebuild strength after spinal cord injury — trial puts it to the test
- Can a smart brain implant outsmart chronic pain?
- Can a new rowing seat help veterans with paralysis row freely?